Filtered By:
Source: EuroIntervention
Condition: Aortic Stenosis
This page shows you your search results in order of date.
Order by Relevance | Date
Total 51 results found since Jan 2013.
Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients at low to intermediate surgical risk: rationale and design of the randomised DEDICATE Trial
EuroIntervention. 2023 Sep 1:EIJ-D-23-00232. doi: 10.4244/EIJ-D-23-00232. Online ahead of print.ABSTRACTTranscatheter aortic valve implantation (TAVI) has become the preferred treatment option for patients with severe aortic stenosis at increased risk for surgical aortic valve replacement (SAVR) and for older patients irrespective of risk. However, in younger, low-risk patients for whom both therapeutic options, TAVI and SAVR, are applicable, the optimal treatment strategy remains controversial, as data on long-term outcomes remain limited. The DEDICATE-DZHK6 Trial is an investigator-initiated, industry-independent, prospe...
Source: EuroIntervention - September 1, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Moritz Seiffert Reinhard Vonthein Helmut Baumgartner Michael A Borger Yeong-Hoon Choi Volkmar Falk Norbert Frey Andreas Hagendorff Christian Hagl Christian Hamm Inke R K önig Ulf Landmesser Steffen Massberg Hermann Reichenspurner Holger Thiele Raphael Tw Source Type: research
Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation
CONCLUSIONS: In patients with severe aortic stenosis and stable coronary artery disease scheduled for TAVI, performance of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies. These results need to be confirmed in randomised clinical trials.PMID:37436190 | DOI:10.4244/EIJ-D-23-00186
Source: EuroIntervention - July 12, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Tobias Rheude Giuliano Costa Flavio Luciano Ribichini Thomas Pilgrim Ignacio J Amat Santos Ole De Backer Won-Keun Kim Henrique Barbosa Ribeiro Francesco Saia Matjaz Bunc Didier Tchetche Philippe Garot Darren Mylotte Francesco Burzotta Yusuke Watanabe Fran Source Type: research
Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR
CONCLUSIONS: Preliminary results from the FIH study with DurAVR THV demonstrate a good safety profile with promising haemodynamic performance sustained at 1 year and restoration of near-normal flow dynamics. Further clinical investigation is warranted to evaluate how DurAVR THV may play a role in addressing the challenge of lifetime management in AS patients.PMID:37334801 | DOI:10.4244/EIJ-D-23-00282
Source: EuroIntervention - June 19, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Susheel K Kodali Paul Sorajja Christopher U Meduri Kari Feldt Jo ão L Cavalcante Pankaj Garg Nadira Hamid Karl K Poon Magnus R M Settergren Marcus R Burns Andreas R ück Janarthanan Sathananthan Alan Zajarias Tamaz Shaburishvili Teona Zirakashvili Maia Z Source Type: research
Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG Study
CONCLUSIONS: The PORTICO NG Study demonstrates low rates of adverse events and PVL up to 1 year in patients at high or extreme surgical risk, confirming the safety and efficacy of the Navitor THV system.PMID:36895190 | DOI:10.4244/EIJ-D-22-01108
Source: EuroIntervention - March 10, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Lars Sondergaard Antony S Walton Stephen G Worthley Dave Smith Bassem Chehab Ganesh Manoharan Gerald Yong Francesco Bedogni Nicholas Bates Michael J Reardon Source Type: research
Routine cerebral embolic protection in transcatheter aortic valve implantation: rationale and design of the randomised British Heart Foundation PROTECT-TAVI trial
EuroIntervention. 2023 Jan 26:EIJ-D-22-00713. doi: 10.4244/EIJ-D-22-00713. Online ahead of print.ABSTRACTTranscatheter aortic valve implantation (TAVI) is an established treatment for aortic stenosis. Cerebral embolic protection (CEP) devices may impact periprocedural stroke by capturing debris destined for the brain. However, there is a lack of high-quality randomised trial evidence supporting the use of CEP during TAVI. The British Heart Foundation (BHF) PROTECT-TAVI trial will address whether the routine use of CEP reduces the incidence of stroke in patients undergoing TAVI. BHF PROTECT-TAVI is a prospective, open-label...
Source: EuroIntervention - January 27, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Rajesh K Kharbanda Alexander David Perkins James Kennedy Adrian P Banning Andreas Baumbach Daniel J Blackman Matthew Dodd Richard Evans David Hildick-Smith Zahra Jamal Peter Ludman Stephen Palmer Rodney Stables Tim Clayton Source Type: research
